4D Molecular Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
FDMT Nasdaq 2830 www.4dmoleculartherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for 4D Molecular Therapeutics, Inc.

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population - Jul 18th, 2026 1:15 pm
4DMT Announces New Employment Inducement Grants - Jul 17th, 2026 2:05 pm
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists - Jun 30th, 2026 2:05 pm
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD - Jun 29th, 2026 6:00 am
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital - Jun 29th, 2026 6:00 am
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker - Jun 26th, 2026 5:30 am
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength? - Jun 23rd, 2026 7:42 am
Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight - May 27th, 2026 6:31 am
4DMT to Participate in Upcoming Investor Conferences - May 27th, 2026 6:00 am
4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You? - May 20th, 2026 6:36 am
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy - May 16th, 2026 6:02 pm
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - May 11th, 2026 8:04 am
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - May 7th, 2026 5:05 pm
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - May 7th, 2026 2:05 pm
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates - May 7th, 2026 6:50 am
electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last? - Apr 10th, 2026 7:57 am
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates - Mar 18th, 2026 3:25 pm
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - Mar 18th, 2026 2:05 pm
4DMT to Participate in Upcoming Investor Meetings - Mar 16th, 2026 6:00 am
4D Molecular Therapeutics Highlights 4D-150 Phase III Momentum, DME Plans, Cash Runway at Leerink Conference - Mar 16th, 2026 4:31 am